# Acne Vulgaris FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/acne-vulgaris

> 2 upcoming FDA catalysts in acne Vulgaris: denifanstat (SGMT) on August 2027 (primary completion); denifanstat (SGMT) on Aug to Nov 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 22, 2025 | [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt) primary completion](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) | BFRI | Acne Vulgaris | completed | "NCT05080764 (Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05080764)) |
| October 1, 2026 | [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt) topline data readout](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) | BFRI | Acne Vulgaris | completed | "NCT05080764 (Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05080764?tab=results)) |
| August 2027 | [Denifanstat primary completion](https://sec-api.dev/pdufa/denifanstat) | SGMT | Acne Vulgaris | scheduled | "NCT07863193 (Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Sagimet Biosciences Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07863193)) |
| Aug to Nov 2027 | [Denifanstat topline data readout](https://sec-api.dev/pdufa/denifanstat) | SGMT | Acne Vulgaris | scheduled | "NCT07863193 (Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Sagimet Biosciences Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07863193)) |

## Drugs

- [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt)](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) (BFRI)
- [Denifanstat](https://sec-api.dev/pdufa/denifanstat) (SGMT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/acne-vulgaris.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Acne Vulgaris FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/acne-vulgaris

```bibtex
@misc{secapidev_indications_acne_vulgaris_20261116,
  title        = {Acne Vulgaris FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/acne-vulgaris}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_acne_vulgaris_20261116","title":"Acne Vulgaris FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/acne-vulgaris","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
